Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen.
Vaccines (Basel)
; 10(3)2022 Mar 21.
Article
in English
| MEDLINE | ID: covidwho-1753699
ABSTRACT
Aims:
To report potential vaccine-induced ocular adverse events following inactivated COVID-19 vaccination (Sinopharm and Sinovac).Methods:
This case series took place at a tertiary referral center in the southeast of China (Xiamen Eye Center in Fujian Province) from February 2021 to July 2021. Patients who received the first dose of inactivated COVID-19 vaccine and developed vaccine-related ocular adverse events within 10 days were included. The diagnosis of vaccine-related ocular adverse events was guided by the World Health Organization causality assessment and the Naranjo criteria.Results:
Ten eyes of seven patients (two male individuals) presenting with ocular complaints following COVID-19 vaccine were included in the study. The mean (SD) age was 41.4 (9.3) years (range, 30-55 years). The mean time of ocular adverse event manifestations was 4.9 days (range, 1-10 days). Three patients were diagnosed with Vogt-Koyanagi-Harada (VKH)-like uveitis, one with multifocal choroiditis, one with episcleritis, one with iritis, and one with acute idiopathic maculopathy. Two patients received the second dose of vaccine. One patient had exacerbation of VKH, and one patient had no symptoms. An aqueous humor analysis in three patients revealed elevated proinflammatory cytokines and negative virus copy. All the patients had transient ocular disturbance and responded well to steroids. No recurrence was noted during 6 months of follow-up.Conclusions:
Potential ocular adverse events should be reported to increase the awareness of the health community for timely detection and proper treatment.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Prognostic study
Topics:
Vaccines
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Vaccines10030482
Similar
MEDLINE
...
LILACS
LIS